RxDoctor Payments Data

Robert Sullivan, MD

Cardiovascular Disease · Oklahoma City, OKNPI 1265896179

Payments from drug & device makers

What this record shows

This record is dominated by grants: $25,500 of the $36,031 with a category attached, or 70.8%. Medtronic accounts for 64.0% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2023 at $30,951 and has fallen 98.3% since, to $520 in 2025. Among cardiovascular disease clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$36,031in general payments, 2019–2025

Across 118 payments — averaging $305.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$23K
  • Abbott$5K
  • Edwards Lifesciences$5K
  • Philips North America LLC$782
  • Shockwave Medical, Inc$605
  • Boston Scientific$471
  • plus $1K from 13 others

What the payments were for

  • Grants$25,50071%
  • Travel & lodging$3,71810%
  • Food & beverage$6,81319%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,031 in reported general payments places this provider in the 95th percentile of 164 cardiovascular disease providers in Oklahoma.

See all cardiovascular disease providers in Oklahoma

Medicare billing

Part B allowed, 2024
$34,518
Medicare patients
108
Services billed
341

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Atorvastatin Calcium13$155
Metoprolol Tartrate20$61

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →